Pan-cancer analysis of disulfidptosis with potential implications in prognosis, immune microenvironment, and drug resistance in human cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Disulfidptosis, a newly identified cell death pathway, is altered in most human cancers. Its gene expression predicts patient prognosis and cancer drug sensitivity, offering new therapeutic avenues.
Area Of Science
- Oncology
- Molecular Biology
- Cell Death Research
Background
- Disulfidptosis is an emerging form of programmed cell death.
- Understanding its role in cancer is crucial for developing new therapies.
Purpose Of The Study
- To systematically assess disulfidptosis-related genes across human cancers.
- To explore the predictive role of disulfidptosis in cancer drug sensitivity.
Main Methods
- Utilized TCGA data to develop a score-level model for disulfidptosis quantification in 33 cancers.
- Analyzed mRNA and protein levels from the Human Protein Atlas.
- Performed multiomics bioinformatic analyses.
Main Results
- Thirty cancers exhibited significantly different disulfidptosis gene expression between normal and tumor tissues.
- Altered disulfidptosis scores correlated with patient prognosis.
- High expression of disulfidptosis genes was linked to drug resistance.
Conclusions
- Disulfidptosis-related genes are dysregulated across numerous human cancers.
- The disulfidptosis score shows potential as a predictive biomarker for drug response.
- Further research into disulfidptosis holds prognostic and therapeutic promise.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.